# Bliss GVS Pharma Limited (BLISSGVS)

> BLISSGVS closed at ₹651.65 on 30 Oct 2026, trailing P/E 43.0, market cap ₹6,929 cr, latest results for the quarter ended 30 Sept 2026. Revenue, profit, ROE, debt, own P/E range and sector-peer comparison from the SEBI filing.

Bliss GVS Pharma Limited (NSE: BLISSGVS) closed at ₹651.65 on 30 Oct 2026, +328.5% over one year, against a 52-week range of ₹118.00 – ₹739.90.

In the quarter ended 30 Sept 2026 (consolidated, filed 29 Oct 2026) it reported revenue of ₹313 cr and net profit of ₹52 cr, a 16.7% net margin; revenue grew 28.2% and profit grew 84.8% year on year.

On four consecutive filed quarters its trailing P/E is 43.0; since 13 May 2025 its own P/E has ranged from 14.8 to 57.3 (median 21.4), and today's reading is higher than 85% of those 363 trading days.

From the balance sheet dated 30 Sept 2026: return on equity 16.2%, ROCE 23.2%, debt-to-equity 0.00, Piotroski F-score 7 of 9.

Against 66 Healthcare peers on NSE: Net margin higher than 62% of 64 sector peers; PBT margin higher than 67% of 64 sector peers; ROE higher than 66% of 64 sector peers.

## Key figures

| Figure | Value |
|---|---|
| Last close | ₹651.65 (30 Oct 2026) |
| Change 1 month / 6 months / 1 year | -5.2% / +148.1% / +328.5% |
| 52-week low – high | ₹118.00 – ₹739.90 |
| Market capitalisation | ₹6,929 cr |
| Trailing P/E | 43.0 |
| Price / book | 5.37 |
| EV / EBITDA | 24.5 |
| Earnings yield | 2.3% |
| TTM EPS | ₹15.16 |
| TTM net profit | ₹161 cr |
| Quarter revenue | ₹313 cr |
| Quarter net profit | ₹52 cr |
| Net margin | 16.7% |
| Revenue growth (YoY) | +28.2% |
| Profit growth (YoY) | +84.8% |
| Return on equity | 16.2% |
| ROCE | 23.2% |
| Debt / equity | 0.00 |
| Current ratio | 4.35 |
| Free cash flow | ₹4 cr |
| Piotroski F-score | 7 / 9 |
| Average daily turnover (50 days) | ₹14.9 cr |

## Questions

### What is the P/E ratio of Bliss GVS Pharma Limited?

Bliss GVS Pharma Limited's trailing P/E is 43.0, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 13 May 2025 its P/E has ranged 14.8–57.3.

### What were Bliss GVS Pharma Limited's latest quarterly results?

For the quarter ended 30 Sept 2026, Bliss GVS Pharma Limited reported revenue of ₹313 cr and net profit of ₹52 cr (consolidated), filed with the exchange on 29 Oct 2026.

### What is Bliss GVS Pharma Limited's ROE?

Return on equity is 16.2% based on the balance sheet dated 30 Sept 2026.

### Does Bliss GVS Pharma Limited have debt?

Debt-to-equity is 0.00 on the balance sheet dated 30 Sept 2026.

### What is BLISSGVS's 52-week high and low?

Over the last 52 weeks to 30 Oct 2026, BLISSGVS traded between ₹118.00 and ₹739.90.

Sector: [Healthcare](https://trinetra.trade/sectors/healthcare) · Page: https://trinetra.trade/fundamentals/BLISSGVS

_TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing._